Aquavit Receives FDA Clearance for Two INDs to Initiate Clinical Trials With Its Botulinum Toxin
NEW YORK, April 29, 2023 /PRNewswire/ -- Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum...
top of page
Search
Aquavit Files IND Application for its Flagship Intradermal Injection of Botulinum Toxin
NEW YORK, April 28, 2023 /PRNewswire/ -- Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum...
WIPO Publishes Aquavit's Methods for Delivering Bioactive Compositions and Formulations to the Skin
NEW YORK, March 23, 2023 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a...
Aquavit Awarded 10M in Damages on Intellectual Property Against Counterfeiters
NEW YORK, March 23, 2023 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") today received a final award in the amount of...
Aquavit Files IND for a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis
NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar...
Aquavit Files Two IND's For Its Botulinum Toxin With FDA
PR Newswire Fri, March 17, 2023 at 3:28 PM PDT·3 min read Announces its IND Submissions to FDA for Aquatox™ at the Annual American...
Aquavit named leading innovator in microneedle-based drug delivery for the medical devices industry
The medical devices industry continues to be a hotbed of innovation, with activity driven by increased need for homecare, preventative...
Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters
NEW YORK, Nov. 3, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment...
Aquavit Pharmaceuticals, Inc. Names Timothy Sherwood Chief Operating Officer
NEW YORK, May 17, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") today announced that it has appointed Senior Vice...
AAD, Industry Collab to Increase Number of Black,Latino, and Indigenous Physicians in Dermatology
Volume 19, No. 4 • April 2022
Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin
NEW YORK, March 24, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. announced today that it has submitted its IND package...
Aquavit Further Prevails Against Counterfeiters in U.S. Following its Recent Victory in Europe
NEW YORK , March 21, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc ("Aquavit") continues to succeed in its intellectual property...
Aquavit's AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO
September 1, 2021; New York, NY Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a...
Patent Granted to Aquavit for Novel RoA and MoA for Bioactive Compositions
May 4, 2021; New York, NY U.S. patent number 10,980,865 [Application Number 14/909,954] was granted to Aquavit Pharmaceuticals, Inc. for...
Aquavit to Introduce A New Botulinum Toxin (DTX-021)
NEW YORK, April 14, 2021 Aquavit Holdings LLC announced today that it acquired an exclusive license to register, market and commercialize...
New Vitamin Supplement Compositions Patent Granted by USPTO
March 19, 2021: New York, NY Aquavit Pharmaceuticals, Inc. (“Aquavit”) announced today that the United States Patent and Trademark Office...
Dr. Sten Vermund, Dean, Yale School of Public Health Congratulates Aquavit Pharmaceuticals
About Dr. Sten Vermund: Dr. Sten Vermund is a pediatrician and infectious disease epidemiologist focused on diseases of low and middle...
Aquavit Wins Trademark Case over AQUAGOLD in European Union Intellectual Property Office
April 15, 2021: New York, NY The European Union Intellectual Property Office (EUIPO) declared that U-BioMed’s falsely registered...
The New Normal: Protect Yourself with Face Masks, & Protect Your Skin with the InnerB System® Mask
NEW YORK, Dec. 2, 2020 We are now living in the "new-normal" era, wearing face masks everywhere. With the extended use of face coverings,...
News: Blog2
bottom of page